XLV vs IBB: How Healthcare Diversification Compares to Biotech ConcentrationThe Motley Fool • 09/24/26
XLV vs. PJP: How Broad Healthcare Diversification Stacks Up to Pharma StocksThe Motley Fool • 09/23/26
Heard on the Street: With the Food and Drug Administration's hard-liners gone, investors are rushing back into rare-disease betsWSJ • 09/16/26
State Street XLV vs. iShares IXJ: Here's How These Healthcare ETFs Stack Up for InvestorsThe Motley Fool • 09/13/26
Midterm Takes Center Stage: What Does It Mean for Markets & ETFs?Zacks Investment Research • 09/11/26
Amgen Falls 10% as Novartis Trial Failure Clouds a Cholesterol Drug Class; NVS Stock Drops 14%24/7 Wall Street • 09/08/26
If the Fed Hikes Interest Rates This Month, History Says This Is the Smartest ETF to Buy Right NowThe Motley Fool • 09/07/26
FDA Nods Lilly-Roche's Alzheimer's Blood Test: Healthcare ETFs to Track NowZacks Investment Research • 08/27/26
Vanguard Health Care ETF vs State Street XLV: Which ETF Is the Better Buy for Investors in 2026?The Motley Fool • 08/08/26